Merrimack discontinues phase 2 SHERLOC study of MM-121 in patients with NSCLC
Merrimack announced termination of the SHERLOC study, its randomized, open-label Phase 2 clinical trial evaluating MM-121 in combination with docetaxel in patients with heregulin positive NSCLC. This decision was made following an interim analysis. October 19, 2018